Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
While myelodysplastic syndrome (MDS) and acute leukemia (AL) are well-known secondary diseases after administration of chemotherapy, particularly alkylating agents, they have only rarely been reported in the context of purine analog treatment. In all cases there was an interval of several months before onset of the secondary disease and cytogenetic analyses showed typical chromosomal aberrations. We report the case of a 68-year old male Caucasian with low-grade lymphoma who developed a MDS during ongoing first-line treatment with the purine analog 2-CDA (Cladribine). Furthermore, a normal karyotype was present initially and at all consecutive control evaluations. Thus, this case represents another rare report of an evolution of purine analog treatment-associated MDS; the absence of cytogenetic aberrations might suggest a different mechanism in the pathogenesis of this secondary disease.
Jäger
Gerald
G
Department of Internal Medicine, Division of Haematology, Karl-Franzens-University, Auenbruggerplatz, Graz, Austria. gerald.jaeger@uni-graz.at
Höfler
Gerald
G
Linkesch
Werner
W
Neumeister
Peter
P
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017338:Cladribine / Q000009:adverse effects* / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*
D000970:Antineoplastic Agents; D017338:Cladribine